EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression.
EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations.
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024.
LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024 LTRN stock results show that Lantern Pharma missed analyst estimates for earnings per share the first quarter of 2024.
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire Keep an eye on machine learning stocks. With big demand, we could be looking at a half-trillion-dollar market by 2030.
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March No AI category went down in February, but 3 did in March - confirming my comment last week that
Six Of Seven AI Stock Categories Increased This Week All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial intelligence technology sector is slowing.
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
Earnings Scheduled For March 18, 2024 Companies Reporting Before The Bell • Niu Techs (
NASDAQ:NIU ) is expected to report earnings for its fourth quarter.
